Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
The ESMO Congress 2021 presented the very latest advances in the treatment of cancer and offered an excellent educational programme, with opportunities for an exchange of ideas among delegates through an enhanced virtual experience.
ESMO Congress 2021: The place where the oncology experts come together, as a community.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
